Literature DB >> 16081955

Genetic diversity among type emm28 group A Streptococcus strains causing invasive infections and pharyngitis.

Nicole M Green1, Stephen B Beres, Edward A Graviss, James E Allison, Allison J McGeer, Jaana Vuopio-Varkila, Rance B LeFebvre, James M Musser.   

Abstract

Genome sequencing of group A Streptococcus (GAS) has revealed that prophages account for the vast majority of gene content differences between strains. Serotype M28 strains are a leading cause of pharyngitis and invasive infections, but little is known about genetic diversity present in natural populations of these organisms. To study this issue, population-based samples of 568 strains from Ontario, Canada; Finland; and Houston, Texas, were analyzed. Special attention was given to analysis of variation in prophage-encoded virulence gene content by a PCR-based method. Thirty and 29 distinct prophage-encoded virulence gene profiles were identified among pharyngitis and invasive infection isolates. Thirteen profiles, representing the majority of the strains, were shared between these two classes of isolates. Significant differences were observed in the frequency of occurrence of certain prophage toxin gene profiles and infection type. M28 strains are highly diverse in prophage-encoded virulence gene content and integration site, supporting the key concept that prophages are critical contributors to GAS genetic diversity and population biology. Nucleotide sequence variation in the emm gene (encodes M protein) was also examined. Only three allelic variants were identified in the hypervariable portion of the emm28 gene. All but one strain had the same inferred amino acid sequence in the first 100 amino acids of the mature M28 protein. In contrast, size differences in the emm28 gene and inferred protein due to variable numbers of C-terminal repeats were common. The presence of macrolide resistance genes (mefA, ermB, and ermTR) was analyzed by PCR, and less than 2% of the strains were positive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081955      PMCID: PMC1233891          DOI: 10.1128/JCM.43.8.4083-4091.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  55 in total

1.  Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland.

Authors:  A Muotiala; H Seppälä; P Huovinen; J Vuopio-Varkila
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

2.  High-resolution genotyping elucidates the epidemiology of group A streptococcus outbreaks.

Authors:  J Stanley; M Desai; J Xerry; A Tanna; A Efstratiou; R George
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

3.  Outbreak of perianal Streptococcus pyogenes infection in a day-care center.

Authors:  H Saxén; A Muotiala; T Rostila; J Vuopio-Varkila
Journal:  Pediatr Infect Dis J       Date:  1997-02       Impact factor: 2.129

4.  The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease.

Authors:  G Colman; A Tanna; A Efstratiou; E T Gaworzewska
Journal:  J Med Microbiol       Date:  1993-09       Impact factor: 2.472

5.  Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study.

Authors:  R Kaul; A McGeer; D E Low; K Green; B Schwartz
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

Review 6.  The surgical team as a source of postoperative wound infections caused by Streptococcus pyogenes.

Authors:  H J Kolmos; R N Svendsen; S V Nielsen
Journal:  J Hosp Infect       Date:  1997-03       Impact factor: 3.926

7.  Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes.

Authors:  J Clancy; J Petitpas; F Dib-Hajj; W Yuan; M Cronan; A V Kamath; J Bergeron; J A Retsema
Journal:  Mol Microbiol       Date:  1996-12       Impact factor: 3.501

8.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group.

Authors:  H D Davies; A McGeer; B Schwartz; K Green; D Cann; A E Simor; D E Low
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

10.  Evaluation of methods for epidemiologic typing of group A streptococci.

Authors:  H Seppälä; J Vuopio-Varkila; M Osterblad; M Jahkola; M Rummukainen; S E Holm; P Huovinen
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

View more
  31 in total

1.  In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Morihiro Iwata; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

2.  The N-terminal domain of the R28 protein promotes emm28 group A Streptococcus adhesion to host cells via direct binding to three integrins.

Authors:  Antonin Weckel; Dorian Ahamada; Samuel Bellais; Céline Méhats; Céline Plainvert; Magalie Longo; Claire Poyart; Agnès Fouet
Journal:  J Biol Chem       Date:  2018-08-27       Impact factor: 5.157

3.  Adaptation of group A Streptococcus to human amniotic fluid.

Authors:  Izabela Sitkiewicz; Nicole M Green; Nina Guo; Ann M Bongiovanni; Steven S Witkin; James M Musser
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

4.  Distribution of phage-associated virulence genes in pharyngeal group a streptococcal strains isolated in Italy.

Authors:  Luca Agostino Vitali; Stefania D'Ercole; Dezemona Petrelli; Maria Chiara Di Luca; Silvia Rombini; Manuela Prenna; Sandro Ripa
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

5.  The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue.

Authors:  Heaven Oliver-Kozup; Karen H Martin; Diane Schwegler-Berry; Brett J Green; Courtney Betts; Arti V Shinde; Livingston Van De Water; Slawomir Lukomski
Journal:  Mol Microbiol       Date:  2012-12-26       Impact factor: 3.501

6.  The intrinsic immunoglobulin g endopeptidase activity of streptococcal Mac-2 proteins implies a unique role for the enzymatically impaired Mac-2 protein of M28 serotype strains.

Authors:  Jenny Johansson Söderberg; Patrik Engström; Ulrich von Pawel-Rammingen
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

7.  MOLECULAR MECHANISMS CONTRIBUTING TO FUZZY EPIDEMICS CAUSED BY GROUP A STREPTOCOCCUS, A FLESH-EATING HUMAN BACTERIAL PATHOGEN.

Authors:  James M Musser
Journal:  Trans Am Clin Climatol Assoc       Date:  2020

8.  M-protein and other intrinsic virulence factors of Streptococcus pyogenes are encoded on an ancient pathogenicity island.

Authors:  Alexandre Panchaud; Lionel Guy; François Collyn; Marisa Haenni; Masanobu Nakata; Andreas Podbielski; Philippe Moreillon; Claude-Alain H Roten
Journal:  BMC Genomics       Date:  2009-04-27       Impact factor: 3.969

9.  Short-term genome evolution of Listeria monocytogenes in a non-controlled environment.

Authors:  Renato H Orsi; Mark L Borowsky; Peter Lauer; Sarah K Young; Chad Nusbaum; James E Galagan; Bruce W Birren; Reid A Ivy; Qi Sun; Lewis M Graves; Bala Swaminathan; Martin Wiedmann
Journal:  BMC Genomics       Date:  2008-11-13       Impact factor: 3.969

10.  Human group A streptococci virulence genes in bovine group C streptococci.

Authors:  Márcia G Rato; Ricardo Bexiga; Sandro F Nunes; Cristina L Vilela; Ilda Santos-Sanches
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.